StockData
Elite Pharmaceuticals Inc logo

Elite Pharmaceuticals Inc (ELTP) stock

ELTPOTCPharmaceutical PreparationsFiscal year ends March 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/30
$0.25−0.00 (-1.37%)

Close on Oct 19, 2026Market cap $283.02MP/E 5.0Yield –

Elite Pharmaceuticals total assets

Total assets on the balance sheet at the end of each period.

Elite Pharmaceuticals's total assets was $139.67M at Jun 30, 2026. For fiscal 2026 it was $138.29M, up 43.5% from the year before. Over ten years it grew 15.9% a year on average. The highest annual figure on record is $138.29M in fiscal 2026.

Annual total assets

PeriodPeriod endValueChange
FY2026Mar 31, 2026$138.29M+43.5%
FY2025Mar 31, 2025$96.39M+15.2%
FY2024Mar 31, 2024$83.65M+104.6%
FY2023Mar 31, 2023$40.90M+16.4%
FY2022Mar 31, 2022$35.15M+34.2%
FY2021Mar 31, 2021$26.19M+4.9%
FY2020Mar 31, 2020$24.96M+2.3%
FY2019Mar 31, 2019$24.40M-21.0%
FY2018Mar 31, 2018$30.88M-10.0%
FY2017Mar 31, 2017$34.31M+8.3%
FY2016Mar 31, 2016$31.67M+22.2%
FY2015Mar 31, 2015$25.92M+6.6%
FY2014Mar 31, 2014$24.32M+118.6%
FY2013Mar 31, 2013$11.13M+7.9%
FY2012Mar 31, 2012$10.31M-12.5%
FY2011Mar 31, 2011$11.79M–

Quarterly total assets

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q1 FY2027CQ2 2026Jun 30, 2026$139.67M+25.4%
Q4 FY2026CQ1 2026Mar 31, 2026$138.29M+43.5%
Q3 FY2026CQ4 2025Dec 31, 2025$126.41M+39.3%
Q2 FY2026CQ3 2025Sep 30, 2025$117.25M+32.9%
Q1 FY2026CQ2 2025Jun 30, 2025$111.34M+26.7%
Q4 FY2025CQ1 2025Mar 31, 2025$96.39M+15.2%
Q3 FY2025CQ4 2024Dec 31, 2024$90.76M+21.5%
Q2 FY2025CQ3 2024Sep 30, 2024$88.20M+24.7%
Q1 FY2025CQ2 2024Jun 30, 2024$87.85M+88.9%
Q4 FY2024CQ1 2024Mar 31, 2024$83.65M+104.6%
Q3 FY2024CQ4 2023Dec 31, 2023$74.70M+41.7%
Q2 FY2024CQ3 2023Sep 30, 2023$70.72M+40.5%
Q1 FY2024CQ2 2023Jun 30, 2023$46.50M-3.3%
Q4 FY2023CQ1 2023Mar 31, 2023$40.90M+16.4%
Q3 FY2023CQ4 2022Dec 31, 2022$52.72M+65.0%
Q2 FY2023CQ3 2022Sep 30, 2022$50.34M+64.4%
Q1 FY2023CQ2 2022Jun 30, 2022$48.11M+60.4%
Q4 FY2022CQ1 2022Mar 31, 2022$35.15M+34.2%
Q3 FY2022CQ4 2021Dec 31, 2021$31.95M+11.4%
Q2 FY2022CQ3 2021Sep 30, 2021$30.62M+10.9%
Q1 FY2022CQ2 2021Jun 30, 2021$29.99M+7.8%
Q4 FY2021CQ1 2021Mar 31, 2021$26.19M+4.9%
Q3 FY2021CQ4 2020Dec 31, 2020$28.67M+19.0%
Q2 FY2021CQ3 2020Sep 30, 2020$27.61M+17.3%
Q1 FY2021CQ2 2020Jun 30, 2020$27.82M+14.6%
Q4 FY2020CQ1 2020Mar 31, 2020$24.96M+2.3%
Q3 FY2020CQ4 2019Dec 31, 2019$24.09M-8.7%
Q2 FY2020CQ3 2019Sep 30, 2019$23.53M-13.9%
Q1 FY2020CQ2 2019Jun 30, 2019$24.28M-14.8%
Q4 FY2019CQ1 2019Mar 31, 2019$24.40M-21.0%
Q3 FY2019CQ4 2018Dec 31, 2018$26.38M-17.8%
Q2 FY2019CQ3 2018Sep 30, 2018$27.32M-14.7%
Q1 FY2019CQ2 2018Jun 30, 2018$28.50M-15.9%
Q4 FY2018CQ1 2018Mar 31, 2018$30.88M-10.0%
Q3 FY2018CQ4 2017Dec 31, 2017$32.07M-11.4%
Q2 FY2018CQ3 2017Sep 30, 2017$32.01M-8.2%
Q1 FY2018CQ2 2017Jun 30, 2017$33.89M–
Q4 FY2017CQ1 2017Mar 31, 2017$34.31M–
Q3 FY2017CQ4 2016Dec 31, 2016$36.20M–
Q2 FY2017CQ3 2016Sep 30, 2016$34.87M–

More Elite Pharmaceuticals figures

See a number that looks wrong?